At a glance
- Originator Pfizer
- Class Aminopyridines; Obesity therapies
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 25 Jan 2000 Phase-II clinical trials in Diabetes mellitus in USA (PO)
- 25 Jan 2000 Phase-II clinical trials in Obesity in USA (PO)